Preclinical Pharmacokinetics

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 253-278

  Mager, Donald E ^a   Ramanathan, Murali ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Macromolecule disposition; Pharmacokinetic data analysis; Preclinical pharmacokinetics

Indexed keywords

EID: 84889835285     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch3b     Document Type: Chapter

References (100)

1. Supersaxo A, Hein W, Steffen H (1990). Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7:167-169.
2. Charman S A, McLennan D N, Edwards G A, et al. (2001). Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm. Res. 18:1620-1626.
3. Charman S A, Segrave A M, Edwards G A, et al. (2000). Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J. Pharm. Sci. 89:168-177.
4. McLennan D N, Porter C J, Edwards, et al. (2003). Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. Pharm Res. 20:1156-1162.
5. McLennan D N, Porter C J, Edwards, et al. (2005). Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep. J. Pharmacol. Exp. Ther. 313:345-351.
6. Odegard P S, Capoccia K L (2005). Inhaled insulin: Exubera. Ann. Pharmacother. 39:843-853.
7. Patton J S, Bukar J G, Eldon M A (2004). Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet. 43:781-801.
8. Braeckman R (1999). Pharmacokinetics and Pharmacodynamics of Protein Therapeutics. In: Rereid (ed.), Peptide and Protein Drug Analysis, University of British Columbia, Vancouver, B.C., pp. 633-639.
9. Ravetch J V, Kinet J P (1991). Fc receptors. Annu. Rev. Immunol. 9:457-492.
10. Lobo E D, Hansen R J, Balthasar J P (2004). Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93:2645-2668.
11. Sugiyama Y, Hanano M (1989). Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm. Res. 6:192-202.
12. Kurschner C, Ozmen L, Garotta G, et al. (1992). IFN-gamma receptor-Ig fusion proteins: Half-life, immunogenicity, and in vivo activity. J. Immunol. 149:4096-4100.
13. Teng M N, Turksen K, Jacobs C A, et al. (1993). Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clin. Immunol. Immunopathol. 69:215-222.
14. Sato T A, Widmer M B, Finkelman F D, et al. (1993). Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J. Immunol. 150:2717-2723.
15. Finkelman F D, Madden K B, Morris S C, et al. (1993). Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. 151:1235-1244.
16. Schobitz B, Pezeshki G, Pohl T, et al. (1995). Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. Faseb. J. 9:659-664.
17. Aderka D, Engelmann H, Maor Y, et al. (1992). Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:323-329.
18. Debets R, Savelkoul H F (1994). Cytokine antagonists and their potential therapeutic use. Immunol. Today. 15:455-458.
19. Klein B, Brailly H (1995). Cytokine-binding proteins: stimulating antagonists. Immunol. Today. 16:216-220.
20. Ramanathan M (1997). A physicochemical modelling approach for estimating the stability of soluble receptor-bound tumour necrosis factor-alpha. Cytokine. 9:19-26.
21. Zapf J, Hauri C, Waldvogel M, et al. (1986). Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J. Clin. Invest. 77:1768-1775.
22. Baumann G, Shaw M A, Amburn K (1994). Circulating growth hormone binding proteins. J. Endocrinol. Invest. 17:67-81.
23. Baumann G, Vance M L, Shaw M A, et al. (1990). Plasma transport of human growth hormone in vivo. J. Clin. Endocrinol. Metab. 71:470-473.
24. Baumann G, Amburn K D, Buchanan T A (1987). The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. J. Clin. Endocrinol. Metab. 64:657-660.
25. Baumann G, Shaw M A, Brumbaugh R C, et al. (1991). Short stature and decreased serum growth hormone-binding protein in the Mountain Ok people of Papua New Guinea. J. Clin. Endocrinol. Metab. 72:1346-1349.
26. Panitch H, Goodin D S, Francis G, et al. (2002). Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. Neurology. 59:1496-1506.
27. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996). Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology. 47:889-894.
28. Rice G P, Paszner B, Oger J, et al. (1999). The evolution of neutralizing anti bodies in multiple sclerosis patients treated with interferon beta-1b. Neurology. 52:1277-1279.
29. Pachner A R (2001). Measurement of antibodies to interferon beta in patients with multiple sclerosis. Arch. Neurol. 58:1299-1300.
30. Rice G (2001). The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch. Neurol. 58:1297-1298.
31. Brambell F W, Hemmings W A, Morris I G (1964). A theoretical model of Gamma-Globulin Catabolism. Nature. 203:1352-1354.
32. Ghetie V, Hubbard J G, Kim J K, et al. (1996). Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur. J. Immunol. 26:690-696.
33. Israel E J, Wilsker D F, Hayes K C, et al. (1996). Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunology. 89:573-578.
34. Junghans R P, Anderson C L (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 93:5512-5516.
35. Harris J M, Chess R B (2003). Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2:214-221.
36. Monfardini C, Schiavon O, Caliceti P, et al. (1995). A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug. Chem. 6:62-69.
37. Hart G W (1992). Glycosylation. Curr. Opin. Cell Biol. 4:1017-1023.
38. Jenkins N, Parekh R B, James D C (1996). Getting the glycosylation right: Implications for the biotechnology industry. Nat. Biotechnol. 14:975-981.
39. Jones J, Krag S S, Betenbaugh M J (2005). Controlling N-linked glycan site occupancy. Biochim. Biophys. Acta. 1726:121-137.
40. Pastan I, Willingham M C (1985). The pathway of endocytosis. In I Pastan, M C Willingham (eds.), Endocytosis: Plenum Press, New York, pp. 1-44.
41. Mufson R A, Gesner T G (1987). Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood. 69:1485-1490.
42. Chapel S, Veng-Pedersen P, Hohl R J, et al. (2001). Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway. J. Pharmacol. Exp. Ther. 298:820-824.
43. Kuter D J, Rosenberg R D (1995). The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 85:2720-2730.
44. Jusko W J (2005). Guidelines for collection and analysis of pharmacokinetic data. In M Leslie, J J Schentag, W E Evans, et al. (eds.), Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring: Applied Therapeutics, Inc., Vancouver, Canada, Chapter 2.
45. Yamaoka K, Nakagawa T, Uno T (1978). Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:547-558.
46. Gibaldi M, Perrier D (1982). Pharmacokinetics, 2nd ed.: Marcel Dekker, Inc., New York.
47. Caprani O, Sveinsdottir E, Lassen N (1975). SHAM, A method for biexponential curve resolution using initial slope, height, area and moment of the experimental decay type curve. J. Theor. Biol. 52:299-315.
48. Tang L, Persky A M, Hochhaus G, et al. (2004). Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93:2184-2204.
49. Yu Z, Tse F L (1995). An evaluation of numerical integration algorithms for the estimation of the area under the curve (AUC) in pharmacokinetic studies. Biopharm. Drug Dispos. 16:37-58.
50. Bellissant E, Sebille V, Paintaud G (1998). Methodological issues in pharmacokineticpharmacodynamic modeling. Clin. Pharmacokinet. 35:151-166.
51. Foster D M (2001). Noncompartmental vs. compartmental approaches to pharmacokinetic analysis. In A J Atkinson, C E Daniels, R L Dedrick, et al. (eds.), Principles of Clinical Pharmacology: Academic Press, New York, pp. 75-92.
52. Gabrielsson J, Weiner D (2000). Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 3rd ed.: Swedish Pharmaceutical Press, Stockholm, Sweden.
53. Sun Y N, Lee H J, Almon R R, et al. (1999). A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. J. Pharmacol. Exp. Ther. 289:1523-1532.
54. Mager D E, Neuteboom B, Efthymiopoulos C, et al. (2003). Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J. Pharmacol. Exp. Ther. 306:262-270.
55. Segrave A M, Mager D E, Charman S A, et al. (2004). Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J. Pharmacol. Exp. Ther. 309:1085-1092.
56. Ramakrishnan R, Cheung W K, Farrell F, et al. (2003). Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 306:324-331.
57. Benincosa L J, Chow F S, Tobia L P, et al. (2000). Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 292:810-816.
58. Bauer R J, Dedrick R L, White M L, et al. (1999). Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm. 27:397-420.
59. Veng-Pedersen P, Chapel S, Al-Huniti, et al. (2003). A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep. J. Pharmacol. Exp. Ther. 306:532-537.
60. Levy G (1994). Pharmacologic target-mediated drug disposition. Clin. Pharmacol. Ther. 56:248-252.
61. Mager D E (2006). Target-mediated drug disposition and dynamics. Biochem. Pharmacol. 72:1-10.
62. Mager D E, Jusko W J (2001). General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28:507-532.
63. Mager D E, Krzyzanski W (2005). Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm. Res. 22:1589-1596.
64. Ferraiolo B L, Mohler M A, Gloff C A (1992). Protein Pharmacokinetics and Metabolism. Plenum Press, New York.
65. Mordenti J, Chen S A, Moore J A, et al. (1991). Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm. Res. 8:1351-1359.
66. Adolph E F (1949). Quantitative relations in the physiological constitutions of mammals. Science. 109:579-585.
67. Boxenbaum H (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10:201-227.
68. West G B, Brown J H (2005). The origin of allometric scaling laws in biology from genomes to ecosystems: Towards a quantitative unifying theory of biological structure and organization. J. Exp. Biol. 208:1575-1592.
69. West G B, Brown J H, Enquist B J (1997). A general model for the origin of allometric scaling laws in biology. Science. 276:122-126.
70. Boxenbaum H, Ronfeld R (1983). Interspecies pharmacokinetic scaling and the Dedrick plots. Am. J. Physiol. 245:R768-R775.
71. Bonate P L, Howard D (2000). Prospective allometric scaling: Does the emperor have clothes? J. Clin. Pharmacol. 40:335-340.
72. Mahmood I (2000). Critique of prospective allometric scaling: does the emperor have clothes? J. Clin. Pharmacol. 40:341-346.
73. Tang H, Mayersohn M (2005). A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. Drug Metab. Dispos. 33:1294-1296.
74. Tang H, Mayersohn M (2005). A novel model for prediction of human drug clearance by allometric scaling. Drug Metab. Dispos. 33:1297-1303.
75. Hu, T M, Hayton W L (2001). Allometric scaling of xenobiotic clearance: Uncertainty versus universality. AAPS PharmSci. 3:E29.
76. Tang H, Mayersohn M (2005). Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab. Dispos. 33:1288-1293.
77. Mordenti J, Osaka G, Garcia K, et al. (1996). Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol. Appl. Pharmacol. 136:75-78.
78. Lave T, Levet-Trafit B, Schmitt-Hoffmann A H, et al. (1995). Interspecies scal-ing of interferon disposition and comparison of allometric scaling with concentration-time transformations. J. Pharm. Sci. 84:1285-1290.
79. Bazin-Redureau M, Pepin S, Hong G, et al. (1998). Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2. Toxicol. Appl. Pharmacol. 150:295-300.
80. Richter W F, Gallati H, Schiller C D (1999). Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab. Dispos. 27:21-25.
81. Lin Y S, Nguyen C, Mendoza J L, et al. (1999). Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288:371-378.
82. Mahmood I (2004). Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J. Pharm. Sci. 93:177-185.
83. Cosson V F, Fuseau E, Efthymiopoulos C, et al. (1997). Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling. J. Pharmacokinet. Biopharm. 25:149-167.
84. Jolling K, Perez Ruixo J J, Hemeryck A, et al. (2005). Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur. J. Pharm. Sci. 24:465-475.
85. Proost J H, Beljaars L, Olinga P, et al. (2006). Prediction of the pharmacokinetics of succinylated human serum albumin in man from in vivo disposition data in animals and in vitro liver slice incubations. Eur. J. Pharm. Sci. 27:123-132.
86. Dedrick R L (1973). Animal scale-up. J. Pharmacokinet. Biopharm. 1:435-461.
87. Gerlowski L E, Jain R K (1983). Physiologically based pharmacokinetic modeling: Principles and applications. J. Pharm. Sci. 72:1103-1127.
88. Nestorov I (2003). Whole body pharmacokinetic models. Clin. Pharmacokinet. 42:883-908.
89. Davies B, Morris T (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
90. Brown R P, Delp M D, Lindstedt S L, et al. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health. 13:407-484.
91. Xu L, Eiseman J L, Egorin M J, et al. (2003). Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J. Pharmacokinet. Pharmacodyn. 30:185-219.
92. Lin J H, Sugiyama Y, Awazu S, et al. (1982). In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J. Pharmacokinet. Biopharm. 10:637-647.
93. Houston J B (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469-1479.
94. Sato H, Sugiyama Y, Sawada Y, et al. (1987). Physiologically based phar macokinetics of radioiodinated human beta-endorphin in rats: An application of the capillary membrane-limited model. Drug Metab. Dispos. 15:540-550.
95. Peng B, Andrews J, Nestorov I, et al. (2001). Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Dev. 11:15-27.
96. Baxter L T, Zhu H, Mackensen D G, et al. (1995). Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 55:4611-4622.
97. Friedrich S W, Lin S C, Stoll B R, et al. (2002). Antibody-directed effector cell therapy of tumors: Analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia. 4:449-463.
98. Galluppi G R, Rogge M C, Roskos L K, et al. (2001). Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: A conference report. Clin. Pharmacol. Ther. 69:387-399.
99. Toutain P L (2002). Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS PharmSci. 4: E38.
100. Mager D E, Wyska E, Jusko W J (2003). Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dispos. 31:510-518.